Day One Biopharmaceuticals earnings were -$95.0M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest DAWN earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$30.3M, down 15.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, DAWN reported annual earnings of -$95.5M, with -49.5% growth. The next DAWN earnings date is Nov 10, 2025.
Day One Biopharmaceuticals Earnings Reports & History FAQ
What were Day One Biopharmaceuticals's earnings last quarter?
On DAWN's earnings call on Invalid Date, Day One Biopharmaceuticals (NASDAQ: DAWN) reported Q2 2025 earnings per share (EPS) of -$0.29, up 480% year over year. Total DAWN earnings for the quarter were -$30.32 million. In the same quarter last year, Day One Biopharmaceuticals's earnings per share (EPS) was -$0.05.
When does Day One Biopharmaceuticals report earnings?
The next DAWN earnings call is Invalid Date. Add DAWN to your watchlist to be reminded of Day One Biopharmaceuticals's next earnings date.
Is Day One Biopharmaceuticals profitable or losing money?
As of the last Day One Biopharmaceuticals earnings report, Day One Biopharmaceuticals is currently losing money. Day One Biopharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$95.00 million, a 43.28% decrease year over year.
What was DAWN's earnings growth in the past year?
As of Day One Biopharmaceuticals's earnings date in Invalid Date, Day One Biopharmaceuticals's earnings has grown year over year. DAWN earnings in the past year totalled -$95.00 million.
What are Day One Biopharmaceuticals's earnings expectations?
The current EPS estimate for Day One Biopharmaceuticals's earnings report in Invalid Date is -$0.29.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.